Important Investor Alert: The Schall Law Firm Announces Class Action Lawsuit Against Intellia Therapeutics, Inc.
Los Angeles, CA – March 7, 2025
The Schall Law Firm, a leading national shareholder rights law firm, announces the filing of a class-action lawsuit against Intellia Therapeutics, Inc. (“Intellia” or “the Company”) (NASDAQ: NTLA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. This class action follows an investigation into allegations that Intellia Therapeutics made false and misleading statements and failed to disclose material information to investors.
Class Period and Eligibility
The class action lawsuit covers investors who purchased Intellia securities during the period from July 30, 2024, to January 8, 2025, inclusive (the “Class Period”).
Alleged Misstatements
The complaint alleges that Intellia Therapeutics made false and/or misleading statements and failed to disclose material information concerning the Company’s business, operations, and prospects. Specifically, the complaint alleges that Intellia failed to disclose that:
- Clinical trial data for its lead product candidate, INT230, was not as positive as represented;
- The Company’s collaboration with Regeneron Pharmaceuticals, Inc. was less promising than portrayed;
- Intellia’s cash position was not as strong as represented;
Impact on Individual Investors
Investors who purchased Intellia securities during the Class Period may be able to recover their losses, with certain deadlines applying. The Schall Law Firm encourages investors who suffered losses to contact the firm before April 14, 2025.
Global Implications
The implications of this class action lawsuit extend beyond Intellia Therapeutics and its investors. It highlights the importance of transparency and accuracy in corporate communications, particularly in the biotech industry. With the increasing focus on gene editing technologies, it is crucial that investors are provided with accurate and timely information to make informed decisions. Failure to do so can result in significant financial harm and regulatory scrutiny.
Conclusion
The Schall Law Firm’s class action lawsuit against Intellia Therapeutics underscores the need for transparency and accuracy in corporate communications. As the biotech industry continues to evolve, it is essential that investors are kept informed of the latest developments, particularly those that could impact their investments. If you purchased Intellia securities during the Class Period and suffered losses, contact The Schall Law Firm today.
The Schall Law Firm represents investors worldwide and specializes in securities class action lawsuits and shareholder rights litigation. The firm is dedicated to achieving superior results for clients and championing their rights as investors. If you have any questions about this class action lawsuit or other recent securities litigations, please contact The Schall Law Firm.
